Display options
Share it on

Food Nutr Res. 2016 Feb 17;60:28373. doi: 10.3402/fnr.v60.28373. eCollection 2016.

Chronic treatment with epigallocatechin gallate reduces motor hyperactivity and affects in vitro tested intestinal motility of spontaneously hypertensive rats.

Food & nutrition research

Maria Assunta Potenza, Monica Montagnani, Carmela Nacci, Maria Antonietta De Salvia

Affiliations

  1. Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy.
  2. Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy; [email protected].

PMID: 26899572 PMCID: PMC4761688 DOI: 10.3402/fnr.v60.28373

Abstract

BACKGROUND: Green tea catechins seem to contribute toward reducing body weight and fat.

OBJECTIVE: We aimed to investigate whether chronic administration of (-)-epigallocatechin-3-gallate (EGCG), the most abundant catechin of green tea, reduces weight gain in spontaneously hypertensive rats (SHR), an animal model of metabolic syndrome, by increasing motor activity and/or by altering gastrointestinal motility.

DESIGN: Nine-week-old SHR were randomly assigned to two groups and treated by gavage for 3 weeks with vehicle dimethyl sulfoxide or EGCG (200 mg/kg/day). Age-matched Wistar-Kyoto (WKY) control rats were treated with vehicle alone. The effect of chronic administration of EGCG was evaluated on open-field motor activity and on ex vivo colonic and duodenal motility. Moreover, in vitro acute effect of 20-min incubation with EGCG (100 µM) or vehicle was evaluated in colonic and duodenal specimens from untreated WKY rats and SHR.

RESULTS: Vehicle-treated SHR were normoglycemic and hyperinsulinemic, and showed a reduction of plasma adiponectin when compared to vehicle-treated WKY rats. In addition, consistent with fasting glucose and insulin values, vehicle-treated SHR were more insulin resistant than age-matched vehicle-treated WKY rats. Chronic treatment for 3 weeks with EGCG improved insulin sensitivity, raised plasma adiponectin levels, and reduced food intake and weight gain in SHR. Vehicle-treated SHR showed increased open-field motor activity (both crossings and rearings) when tested after each week of treatment. The overall hyperactivity of vehicle-treated SHR was significantly reduced to the levels of vehicle-treated WKY rats after 2 and 3 weeks of EGCG treatment. Colonic and duodenal preparations obtained from SHR chronically treated in vivo with EGCG showed reduced responses to carbachol (0.05-5 µM) and increased inhibitory response to electrical field stimulation (EFS, 1-10 Hz, 13 V, 1 msec, 10-sec train duration), respectively. In vitro acute EGCG incubation (100 µM, 20 min) of colonic and duodenum strips obtained from untreated SHR and WKY rats showed a reduced contractile colonic response to a fixed dose of carbachol (1.5 µM) only in SHR with respect to its own vehicle, whereas the inhibitory duodenal response to a fixed EFS frequency (5 Hz) was significantly reduced in both WKY rats and SHR groups with respect to their own vehicle.

CONCLUSIONS: These data suggest that EGCG affects body weight gain in rats and this effect seems to be due to the altered intestinal motility and not to increased motor activity.

Keywords: colon; duodenum; green tea; weight gain

References

  1. Front Microbiol. 2014 Aug 20;5:434 - PubMed
  2. Am J Physiol Endocrinol Metab. 2013 Sep 15;305(6):E679-86 - PubMed
  3. Clin Cancer Res. 2005 Jun 15;11(12):4627-33 - PubMed
  4. Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):53-8 - PubMed
  5. Obes Res. 2004 Nov;12(11):1723-32 - PubMed
  6. PLoS One. 2014 Feb 03;9(2):e85520 - PubMed
  7. Obes Res. 2003 Sep;11(9):1088-95 - PubMed
  8. Br J Nutr. 2011 Dec;106(12 ):1880-9 - PubMed
  9. Pharmacol Res. 2011 Aug;64(2):123-35 - PubMed
  10. J Nutr Biochem. 2014 Jan;25(1):1-18 - PubMed
  11. Nutrients. 2013 Sep 26;5(10):3779-827 - PubMed
  12. Rev Neurosci. 2011;22(3):365-71 - PubMed
  13. Am J Clin Nutr. 2010 Jan;91(1):73-81 - PubMed
  14. Clin Cancer Res. 2003 Aug 15;9(9):3312-9 - PubMed
  15. Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):351-4 - PubMed
  16. J Nutr Biochem. 2011 Jan;22(1):1-7 - PubMed
  17. Life Sci. 2014 Nov 24;118(2):200-5 - PubMed
  18. J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10 - PubMed
  19. Am J Physiol Endocrinol Metab. 2007 May;292(5):E1378-87 - PubMed
  20. J Nutr Biochem. 2014 May;25(5):557-64 - PubMed
  21. Auton Neurosci. 2009 Jan 28;145(1-2):50-4 - PubMed
  22. Neuropharmacology. 2009 Dec;57(7-8):619-26 - PubMed
  23. Eur J Pharmacol. 2004 Oct 1;500(1-3):177-85 - PubMed
  24. Arch Microbiol. 2014 Oct;196 (10 ):681-95 - PubMed
  25. Neurosci Biobehav Rev. 2000 Jan;24(1):31-9 - PubMed
  26. Neurogastroenterol Motil. 2008 Nov;20(11):1251-62 - PubMed
  27. Life Sci. 2010 Mar 13;86(11-12):410-5 - PubMed
  28. Nutr Metab (Lond). 2014 Jan 07;11(1):3 - PubMed

Publication Types